Literature DB >> 20637989

Optic neuritis.

David Clark1, Workayehu Kebede, Eric Eggenberger.   

Abstract

Optic neuritis usually presents with painful monocular vision loss in younger patients. Spontaneous improvement in vision occurs over weeks, and treatment with high-dose intravenous steroids increases the rate but not extent of visual recovery. Risk of progression to multiple sclerosis (MS) is largely dictated by baseline brain magnetic resonance imaging (MRI). Those with a normal MRI finding at the time of optic neuritis diagnosis have a lower rate of progression to multiple sclerosis than those with T2 hyperintense white matter lesions on MRI. High-dose intravenous steroids should be considered acutely in optic neuritis, and disease-modifying therapy should be considered in patients at high risk of MS as defined by MRI. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20637989     DOI: 10.1016/j.ncl.2010.03.001

Source DB:  PubMed          Journal:  Neurol Clin        ISSN: 0733-8619            Impact factor:   3.806


  3 in total

1.  Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis.

Authors:  Oliver W Gramlich; Stephanie C Joachim; Philip F Gottschling; Panagoitis Laspas; Clemens S Cuny; Norbert Pfeiffer; Franz H Grus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-23       Impact factor: 3.117

2.  High sensitivity of diffusion tensor imaging in discriminating idiopathic demyelinating optic neuritis.

Authors:  Yan Zhang; Si-Hai Wan; Gui-Jun Wu; Xue-Lin Zhang
Journal:  Int J Ophthalmol       Date:  2016-07-18       Impact factor: 1.779

Review 3.  Autoimmune disease of head and neck, imaging, and clinical review.

Authors:  Alireza Paydar; Zachary B Jenner; Tyrell J Simkins; Yu-Ming Chang; Lotfi Hacein-Bey; Arzu Ozturk; Andrew Birkeland; Reza Assadsangabi; Osama Raslan; Ghazal Shadmani; Michelle Apperson; Vladimir Ivanovic
Journal:  Neuroradiol J       Date:  2022-05-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.